* AnaptysBio Inc ANAB.OQ ANAB.O is expected to show a
rise in
quarterly revenue when it reports results on August 7
(estimated).
* The San Diego California-based company is expected to
report a
173.2% increase in revenue to $3.322 million from $1.22 million
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for AnaptysBio Inc is
for a
loss of $1.70 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for AnaptysBio
Inc is
$28.5, above its last closing price of $19.11.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -1.08 -1.05 -1.58 Missed -50.8
Dec. 31 2023 -0.96 -0.96 -0.93 Beat 2.8
Sep. 30 2022 -0.65 -0.72 -1.18 Missed -63.1
Jun. 30 2022 -0.89 -1.02 -1.15 Missed -12.6
Mar. -1.02 -0.99 -1.31 Missed -31.7
31 2022
Dec. 31 2021 5.54 2.57 -1.13 Missed -143.9
Sep. 30 2021 -0.93 -0.91 -0.24 Beat 73.6
Jun. 30 2021 -0.11 -0.11 -0.02 Beat 81.3
This summary was machine generated August 4 at 12:42 GMT. All
figures in US dollars unless otherwise stated